Multiple Myeloma

>

Latest News

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.
Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

August 4th 2025

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.
CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

August 1st 2025

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.
FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma

July 30th 2025

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma

July 26th 2025

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.
Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

July 25th 2025

Latest CME Events & Activities

More News

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 10th 2023

Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.

Teclistamab Plus Talquetamab in RRMM: Data from the RedirecTT-1 Study

Teclistamab Plus Talquetamab in RRMM: Data from the RedirecTT-1 Study

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS
November 9th 2023

Joselle Cook, M.B.B.S., discusses the RedirecTT-1 trial combining teclistamab and talquetamab for patients with relapsed/refractory multiple myeloma, noting high response rates even in high-risk myeloma but concerns about long-term resistance.

Talquetamab in RRMM: Results From MonumenTAL-1

Talquetamab in RRMM: Results From MonumenTAL-1

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS
November 9th 2023

Dr Binod Dhakal discusses response rates and toxicities seen with recently approved bispecific antibodies talquetamab in patients with heavily pretreated multiple myeloma, noting high response rates even after CAR-T, but also unique side effects.

Experts on MM

Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC
November 7th 2023

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

A panel of 4 experts on multiple myeloma seated at a long table

Recent Data on Bispecific Antibodies in Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 7th 2023

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

Experts on MM

Patient Scenario: Management of Multiple Myeloma With Talquetamab Therapy

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC
November 7th 2023

Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.

A panel of 4 experts on multiple myeloma seated at a long table

Multiple Myeloma Treatment: Patient Profiles

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
November 7th 2023

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 3rd 2023

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Cross Q&A: Retrospective Study of Patients With MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 3rd 2023

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS
November 2nd 2023

Dr Luciano Costa discusses treatment options for patients with multiple myeloma with early vs late relapse, noting that those with early aggressive relapse have limited options and often rapidly exhaust available therapies, emphasizing the need for newer agents like bispecific antibodies.

Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma

Patient Case Presentation: A 47-Year-Old Man With Multiple Myeloma

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS
November 2nd 2023

Binod Dhakal, MD, presents the case of a young man with aggressive relapsed multiple myeloma to the panel for discussion.

Experts on multiple myeloma

Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC
October 31st 2023

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.

A panel of 4 experts on multiple myeloma seated at a long table

Treatment Decision-Making in Early-Relapse MM

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
October 31st 2023

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

A panel of 4 experts on multiple myeloma seated at a long table

Recent Data in the Management of Early-Relapse Multiple Myeloma

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD
October 31st 2023

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Outcomes After Biochemical or Clinical Progression in Patients with MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 27th 2023

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 27th 2023

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

Preclinical Characterization of ISB 1342, a CD38 × CD3 T-Cell Engager for Relapsed/Refractory Multiple Myeloma

American Society for Transplantation and Cellular Therapy
October 25th 2023

ISB 1342 has shown improved safety and efficacy for patients with relapsed/refractory multiple myeloma.

Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML

ONCOLOGY Staff
October 20th 2023

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 20th 2023

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 20th 2023

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma

ONCOLOGY Staff
October 19th 2023

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

A panel of 4 experts on multiple myeloma seated at a long table

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 18th 2023

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

A panel of 4 experts on multiple myeloma seated at a long table

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 18th 2023

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Ludovic Saba, MD;Kevin S. Landau, MD;Silvia Bunting, MD;Chakra P. Chaulagain, MD
October 17th 2023

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 13th 2023

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

The host of Cancer Network's Face-Off program shown with an introductory slide

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 13th 2023

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

A panel of 4 experts on multiple myeloma seated at a long table

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 11th 2023

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

A panel of 4 experts on multiple myeloma seated at a long table

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD
October 11th 2023

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

Experts on MM

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS
October 10th 2023

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

Looking Ahead in the Multiple Myeloma Treatment Landscape

Looking Ahead in the Multiple Myeloma Treatment Landscape

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS
October 4th 2023

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

<1
...
141516171819202122
...
65>